Last reviewed · How we verify
Helicocerin (cerulenin)
Helicocerin (generic name: cerulenin) is a drug. It is currently in unknown development.
Helicocerin works by inhibiting the activity of coagulation factor XIII A chain, a protein involved in blood clotting.
Helicocerin, also known as cerulenin, is a small molecule modality targeting coagulation factor XIII A chain. Its exact drug class is unknown, and it has not been approved by the FDA for any indications. As a result, its commercial status, half-life, bioavailability, and generic manufacturers are also unknown. Further research is needed to fully understand its potential as a therapeutic agent. Its safety profile and efficacy have not been extensively studied.
At a glance
| Generic name | cerulenin |
|---|---|
| Target | Coagulation factor XIII A chain, Fatty acid synthase, Pol polyprotein |
| Therapeutic area | Hematology |
| Phase | unknown |
Mechanism of action
Think of blood clotting like a glue that holds a cut together. Coagulation factor XIII A chain is a key part of this glue, helping to strengthen the clot and keep it from falling apart. Helicocerin blocks this glue from working properly, which can help prevent excessive blood clotting.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Helicocerin CI brief — competitive landscape report
- Helicocerin updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Helicocerin
What is Helicocerin?
How does Helicocerin work?
What is the generic name of Helicocerin?
What development phase is Helicocerin in?
What does Helicocerin target?
Related
- Target: All drugs targeting Coagulation factor XIII A chain, Fatty acid synthase, Pol polyprotein
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Hematology
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing